Antibody therapy for histoplasmosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/36512 |
Resumo: | Albert Einstein College of Medicine. Department of Medicine. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA. |
id |
CRUZ_d71e75b52b82d8d10d854cb936878628 |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/36512 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Nosanchuk, Joshua D.Zancopé-Oliveira, Rosely M.Hamilton, Andrew J.Guimarães, Allan J.2019-10-17T12:53:58Z2019-10-17T12:53:58Z2012NOSANCHUK, Joshua D. et al. Antibody therapy for histoplasmosis. Frontiers in Microbiology, v. 3, n. 21, p. 1-7, Feb. 2012.1664-302Xhttps://www.arca.fiocruz.br/handle/icict/3651210.3389/fmicb.2012.000211664-302XengFrontiers MediaAntibody therapy for histoplasmosisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleAlbert Einstein College of Medicine. Department of Medicine. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA.Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Laboratório de Micologia. Setor de Imunodiagnóstico. Rio de Janeiro, RJ, Brasil.Kings College. Guys Hospital. Dermatology Laboratory. London, UK.Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Professor Paulo de Góes. Departmento de Imunologia. Rio de Janeiro, RJ, Brasil.The endemic human pathogenic fungus Histoplasma capsulatum is a major fungal pathogen with a broad variety of clinical presentations, ranging from mild, focal pulmonary disease to life-threatening systemic infections. Although azoles, such as itraconazole and voriconazole, and amphotericin B have significant activity against H. capsulatum, about 1 in 10 patients hospitalized due to histoplasmosis die. Hence, new approaches for managing disease are being sought. Over the past 10 years, studies have demonstrated that monoclonal antibodies (mAbs) can modify the pathogenesis of histoplasmosis. Disease has been shown to be impacted by mAbs targeting either fungal cell surface proteins or host co-stimulatory molecules. This review will detail our current knowledge regarding the impact of antibody therapy on histoplasmosis.Histoplasma capsulatumHistoplasmosisAntibodyHistone 2BHeat shock protein 60M antigenCo-stimulationinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txttext/plain1748https://www.arca.fiocruz.br/bitstream/icict/36512/1/license.txt8a4605be74aa9ea9d79846c1fba20a33MD51ORIGINALve_Nosanchuk_Joshua_etal_INI_2012.pdfve_Nosanchuk_Joshua_etal_INI_2012.pdfapplication/pdf3932936https://www.arca.fiocruz.br/bitstream/icict/36512/2/ve_Nosanchuk_Joshua_etal_INI_2012.pdf9deaf08640346610d752288faa27314fMD52TEXTve_Nosanchuk_Joshua_etal_INI_2012.pdf.txtve_Nosanchuk_Joshua_etal_INI_2012.pdf.txtExtracted texttext/plain45084https://www.arca.fiocruz.br/bitstream/icict/36512/3/ve_Nosanchuk_Joshua_etal_INI_2012.pdf.txt0fd54e7e700c6bdfc01092277bff4478MD53icict/365122019-10-18 02:01:49.198oai:www.arca.fiocruz.br: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Repositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352019-10-18T05:01:49Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Antibody therapy for histoplasmosis |
title |
Antibody therapy for histoplasmosis |
spellingShingle |
Antibody therapy for histoplasmosis Nosanchuk, Joshua D. Histoplasma capsulatum Histoplasmosis Antibody Histone 2B Heat shock protein 60 M antigen Co-stimulation |
title_short |
Antibody therapy for histoplasmosis |
title_full |
Antibody therapy for histoplasmosis |
title_fullStr |
Antibody therapy for histoplasmosis |
title_full_unstemmed |
Antibody therapy for histoplasmosis |
title_sort |
Antibody therapy for histoplasmosis |
author |
Nosanchuk, Joshua D. |
author_facet |
Nosanchuk, Joshua D. Zancopé-Oliveira, Rosely M. Hamilton, Andrew J. Guimarães, Allan J. |
author_role |
author |
author2 |
Zancopé-Oliveira, Rosely M. Hamilton, Andrew J. Guimarães, Allan J. |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Nosanchuk, Joshua D. Zancopé-Oliveira, Rosely M. Hamilton, Andrew J. Guimarães, Allan J. |
dc.subject.en.pt_BR.fl_str_mv |
Histoplasma capsulatum Histoplasmosis Antibody Histone 2B Heat shock protein 60 M antigen Co-stimulation |
topic |
Histoplasma capsulatum Histoplasmosis Antibody Histone 2B Heat shock protein 60 M antigen Co-stimulation |
description |
Albert Einstein College of Medicine. Department of Medicine. New York, NY, USA / Albert Einstein College of Medicine. Department of Microbiology and Immunology. New York, NY, USA. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012 |
dc.date.accessioned.fl_str_mv |
2019-10-17T12:53:58Z |
dc.date.available.fl_str_mv |
2019-10-17T12:53:58Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
NOSANCHUK, Joshua D. et al. Antibody therapy for histoplasmosis. Frontiers in Microbiology, v. 3, n. 21, p. 1-7, Feb. 2012. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/36512 |
dc.identifier.issn.pt_BR.fl_str_mv |
1664-302X |
dc.identifier.doi.none.fl_str_mv |
10.3389/fmicb.2012.00021 |
dc.identifier.eissn.none.fl_str_mv |
1664-302X |
identifier_str_mv |
NOSANCHUK, Joshua D. et al. Antibody therapy for histoplasmosis. Frontiers in Microbiology, v. 3, n. 21, p. 1-7, Feb. 2012. 1664-302X 10.3389/fmicb.2012.00021 |
url |
https://www.arca.fiocruz.br/handle/icict/36512 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Frontiers Media |
publisher.none.fl_str_mv |
Frontiers Media |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/36512/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/36512/2/ve_Nosanchuk_Joshua_etal_INI_2012.pdf https://www.arca.fiocruz.br/bitstream/icict/36512/3/ve_Nosanchuk_Joshua_etal_INI_2012.pdf.txt |
bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 9deaf08640346610d752288faa27314f 0fd54e7e700c6bdfc01092277bff4478 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1813008969223897088 |